Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FDA advises LLY it wants AdCom meeting. Portends delay. Meanwhile NVO CEO was interviewed on CNBC-TV this morning, repeats NVO’s PR warning dated in January 2024 that it will not have manufacturing capacity to fill demand for its weight loss drug until 2006(?).
Still unusual for NVO CEO to appear on TV to reiterate old news. 3-5 minute interview.
Did you see NVO’s CEO on CNBC-TV this morning, saying it would be years(2026) before NVO had sufficient manufacturing capacity to produce enough Ozempic to compete with LLY?
Repeat the question posted previously: A.S. and his ANIP and MedPage possible M&A activities.
NVO’s Wegovy was just given FDA approval for treatment of CVDs, per CNBC-TV alert. No AMRN worries here(?).The CEO of NVO appeared on CBC-TV earlier this morning, saying they had manufacturing capacity problems for Ozempic and that it would be a number of years before NVO could catch up with LLY. Wegovy and Ozempic are the same molecule. Am I missing something? Does NVO have sufficient manufacturing capacity for Wegovy because it is a different dosage form? Anybody know from Europe?
I wonder whether ANIP(Schwarz) or MedPage(Schwarz) has contacted CDMO for ANY reason, potential customer or otherwise. See ANIP PRs dated 11/2023 to date, available from TD Ameritrade and ANIP IHub board.
You might add LTRN as a stock to look at, recent PRs dated 11/28/2003 up to yesterday, available from TD Ameritrade.
No one has responded yet to a question I had about LEXX, and its proprietary drug delivery system that is said to improve the way molecules(like VKTX has) enter the bloodstream. See the various PRs of LEXX dated in January 2024, available from TD Ameritrade. The clinical trials of LEXX are early, but both company shares are + substantially this year. The term “blockbuster” is used to describe the combination of the various VKTX molecules in its pipeline and the LEXX delivery system.
PFE just won a suit in the 2nd Circuit Court of Appeals that involved its diversity fellowship program. PFE share price jumped as a result to current $27.13.
See BIEL PR dated 2/23/2024. Delayed market reaction that was not priced in to current share price? Or shorts moving out?
Perhaps it is the result of a delayed market reaction to the ATNM PR dated 2/28/2024.
Identity of judges on panel D will be known when we arrive on 2nd floor by 9:30 a.m. Thanks for the update. Spouse and I plan to be there.
A new notice of allowance for a patent application, titled:
Compositions And Methods For Detecting Predisposition To Cardiovascular Disease.
I wouldn’t phrase it that way, but we now have > 20k% return on original investment in NVDA.
I have a minor amount of shares of LWLG with a minor loss. Ask Steve Schietz(sp?) if he understands the quote from me that you posted. He liked Polestar. At the moment I spend more time trying to keep up with the Magnificent 7 in our portfolios, headed by NVDA that I bought split-adjusted 755 shares at cost of $4.31 about a decade ago. The auto market is a subset along with biotech(you might check VKTX and LEXX in 2023-2024). All for now. A lunch or dinner should help us understand each other.
I see $188.20 on 3/01/2024.
Polestar EVs are no longer funded by Volvo, per CNBC-TV. Simultaneously, I have seen many more Volvo and Polestar ads on the TV channels we watch, sports and finance channels particularly.
Nuke, I think I have read everything DMC posts on AMRN IHub board in the same manner I previously suggested to you. I do not accept cookies, and I freely read all articles. I do not detect further spam mail as a result. Is Safari an option for you?
I do not cut and paste articles that I see when using my IPad. I sometimes cut and paste when using my main computer, much easier for me.
I just got an alert that Haley won the electoral votes in the District of Columbia.
Try reading the entire article w/o accepting cookies. I was able to read all 3 articles in their entirety. Thanks, DMC8.
Nonesense. Some banks, like NYCB, can’t even run their own business. Wells Fargo didn’t do so well either.
What about the new dosage form Vascepa is in, discussed extensively here recently?
It doesn’t have to own a plant, but it does need a plant that will make its pipeline of molecules better than the Indiana plant of CTLT (NOVO NORDISK) that just got slapped with a warning letter from FDA. I suggested CDMO whose reactor plants have always been FDA approved for good manufacturing methods. Avid Bioservices (CDMO) has supplied raw material to HALO for years to make its Enhanze delivery system for molecules e.g., JNJ’s Darzalex.
Are you aware of LEXX? Said to have a delivery system for molecules like VKTX has that will turn both into a blockbuster.
I understand that VKTX has no facilities with reactors capable of making its pipeline of molecules. CDMO has an expanded capacity plant up the coast from San Diego in Tustin, and a wholly new plant further up the coast near John Wayne airport. GILD has plants in Forest City, and JNJ has plants in South San Francisco. What do you hear on the topic?
Thanks for those 3 graphics, CaptBeer. All positive for AMRN’s future.
Don’t forget that the 52 week low was back in late November, early December, $0.65/share.
Holt told you how we are winning. You are flying blind and deaf w/o your reading glasses and hearing aids in. Do you need prescriptions? Read the entire transcript when you have time
No embarrassment from Holt. Shorts are gettin out from day low of $1.05. Now trading at $1.10 on volume exceeding average 10 day volume. You and PDude need to read the entire transcript from this early morning earnings call.
We have 500 shares of HALO, cost basis of $12.32 in a taxable account, LTCG. Spouse( retired JNJ regulatory attorney, M.D., JD) and I are looking for cash to place HALO in my still extant SEP-IRA account. Other completed mergers in IRA have supplied cash(IMGN, GRCL). Buying shares of VKTX and low-priced LEXX in that IRA looked more advantageous to us so far. More dividends from 3200 shares of GILD in that IRA will provide cash. We use JNJ dividends to pay for trips, and other living expenses as needed. You might look at CPRX, AMRN and CDMO as turnarounds also.
Holt said nothing that I view as negative in the opening segment of that conference call. Very positive, including AMRN abstracts, to be presented at conference in early April. About time, IMO, to adopt Holt’s optimism and stop yammering about negatives seen in AMRN’s future.
The OZEMPIC Revolution premiers tonight on CNBC- TV tonight at 10 pm, as discussed in a long 10-15 minute segment on CNBC-TV today. CVD, blood pressure control, weight loss drugs were discussed on that channel with Jared Holtz, David Faber and Mellissa Lee, ~ 10-35 to 10-50 am. today(Lee interviewed Amarin’s JT 4-5 years ago. JT said “It works”). Amarin shareholders and Insurance sector have already discovered the huge costs it is about to bear, with a third of just the U.S. 330 million population, adults and children, being obese. Insurance companies are looking for lees costly alternatives to the lifetime costs of drugs marketed by LLY, NVO, AZN of ~ $1000/month. VKTX was specifically discussed and LEXX(ads) were visible in that long CNBC-TV interview
LEXX has new delivery system for improved delivery of CVD, blood pressure meds, caffeine delivery to sports stars, weight loss meds like Rybelsus, Ozempic, nicotine delivery( Altria has already signed with LEXX).
It is logical that Viking would use a West Coast facility for making its oral( liquid capsule or solid pill) or injectable form of its weight loss med or its dementia/AD med. HALO’s CEO is attending 3 conferences in March; she is reported to not have attended the JPM conference in January. VKTX is located in San Diego. CDMO has an updated reactor facility in Tustin and a totally new reactor plant near John Wayne airport, a little further north from Tustin. Forest City and south San Francisco, homes of GILD and JNJ reactor/manufacturing facilities, are still further north. CDMO is a supplier to HALO. See my posts on the ANIP board re former CDMO BOD member Arthur Shwartz and his travels since.
GILD is providing at least $12 miliion in grant money over 3 years to scores of institutions, states and cities scattered around the country to help women and transgenders to combat HIV. Will this program make Biktarvy available, or will it make VKTX oral/injectable med available, or both. The bigger question is whether GILD will use its remaining cash $$$ to acquire/merge with VKTX, IMO.
From CDMO to ANIP to MedPharm. Lots of catalysts for future acquisitions of either or both. Thanks dasgrunt, Jtfm, Silvr for the continued due diligence. CDMO, ANIP and AMRN share prices each closed + today, along with our two largest equity holdings, NVDA and VCEL. We purchased 755 shares NVDA at a split adjusted cost basis of $4.31 per share over a decade ago for a total LTCG gain today of ~ $592,893/share, 18,233 gain%.
Amarin is like a mock Statue of Liberty laying on her side in Arlington, Virginia resting in repose or like the Moon Shot Odysseus hitting a rock in the landing crater but doing work and creating market value with the remaining devices attached to the still vertical legs, see LUNR. With insider buying and the planned share buybacks planned for later this year, Amarin is only a short distance from a share price of $2.5/share, to rise to former share prices of $5, $10, $20 sooner than people think. That is my current opinion.
Guidance on future earnings, next quarter or next 6 months or next year(s), can be an important factor that often determines the direction of share price, + or -. We are diversified, and have seen such guidance determine share price and market value of shares in other of our investments, e.g., NVDA, VCEL, our two largest equity market value investments.
M and I are both members of the CAFC bar. We plan to attend in person, not virtually. Earnings are scheduled for 2/29/2024, another factor in multi variable situation we find ourselves in.
Why 4/2/2024? AMRN’s earnings are 2/29/2024 when we expect a corporate update discussion, including Q&A from analysts that may affect share price.
CNBC-TV, Washington Post, share price of LUNR, NASA communications among others.
An alert: LUNR just landed on the moon, a historic first. NVDA collaborated in that history.
Kiwi, I do not have enough capital invested in either CDIO or HSCS to be concerned whether any other company like privately held Anumana has first mover advantage. I did find it interesting that CDIO’s algorithm is known by Cleveland Clinic perhaps as a reference point or as a tool to be incorporated into any Anumana or Cleveland Clinic algorithm in use or to be further developed.
Re other companies: IOVA obtained late FDA approval for its molecule as a treatment for metastatic melanomas. Monday should be interesting, eh? The molecule might be a cure; it does inhibit further metastases for unknown lengths of time.